The potential role of immunotherapy to treat colorectal cancer

Manik Amin, Albert Lockhart

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Introduction: Colorectal cancer (CRC) is the fourth most common cancer and the second leading cause of cancer-related death worldwide. Surgery, chemotherapy, radiation therapy and anti-angiogenic therapies form the backbone of treatment for CRC in various stages. Immunotherapy is frequently used either alone or in combination with chemotherapy for the treatment of various cancers such as melanoma, prostate cancer and renal cell cancer. Current CRC research is moving forward to discover ways to incorporate immunotherapies into the treatment of CRC.Areas covered: The aim of this review is to summarize the potential role of immunotherapy in CRC. Herein, the authors provide a brief overview of immune modulatory cells, immune surveillance and escape in CRC. They also review vaccine trials in addition to cytokines and monoclonal antibodies. This coverage includes ongoing trials and checkpoint inhibitors such as cytotoxic T lymphocyte antigen-1, programmed cell death-1, and PDL1.Expert opinion: Checkpoint inhibitors in combination with either chemotherapy or chemo-antiangiogenic-therapy may represent a future therapeutic approach for CRC incorporating immune system targeting. Given the success of immune-based therapy in other tumor types, the authors anticipate that a similar breakthrough in CRC will be forthcoming.

Original languageEnglish (US)
Pages (from-to)329-344
Number of pages16
JournalExpert Opinion on Investigational Drugs
Volume24
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Immunotherapy
Colorectal Neoplasms
Therapeutics
Drug Therapy
Neoplasms
Second Primary Neoplasms
Viral Tumor Antigens
Expert Testimony
Cytotoxic T-Lymphocytes
Combination Drug Therapy
Renal Cell Carcinoma
Immune System
Melanoma
Prostatic Neoplasms
Cell Death
Radiotherapy
Vaccines
Monoclonal Antibodies
Cytokines
Research

Keywords

  • Colorectal cancer
  • Immune modulatory cells
  • Immune surveillance
  • Immunotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The potential role of immunotherapy to treat colorectal cancer. / Amin, Manik; Lockhart, Albert.

In: Expert Opinion on Investigational Drugs, Vol. 24, No. 3, 01.01.2015, p. 329-344.

Research output: Contribution to journalReview article

@article{bba4eca79dad4bdab8178ac812ef6e7c,
title = "The potential role of immunotherapy to treat colorectal cancer",
abstract = "Introduction: Colorectal cancer (CRC) is the fourth most common cancer and the second leading cause of cancer-related death worldwide. Surgery, chemotherapy, radiation therapy and anti-angiogenic therapies form the backbone of treatment for CRC in various stages. Immunotherapy is frequently used either alone or in combination with chemotherapy for the treatment of various cancers such as melanoma, prostate cancer and renal cell cancer. Current CRC research is moving forward to discover ways to incorporate immunotherapies into the treatment of CRC.Areas covered: The aim of this review is to summarize the potential role of immunotherapy in CRC. Herein, the authors provide a brief overview of immune modulatory cells, immune surveillance and escape in CRC. They also review vaccine trials in addition to cytokines and monoclonal antibodies. This coverage includes ongoing trials and checkpoint inhibitors such as cytotoxic T lymphocyte antigen-1, programmed cell death-1, and PDL1.Expert opinion: Checkpoint inhibitors in combination with either chemotherapy or chemo-antiangiogenic-therapy may represent a future therapeutic approach for CRC incorporating immune system targeting. Given the success of immune-based therapy in other tumor types, the authors anticipate that a similar breakthrough in CRC will be forthcoming.",
keywords = "Colorectal cancer, Immune modulatory cells, Immune surveillance, Immunotherapy",
author = "Manik Amin and Albert Lockhart",
year = "2015",
month = "1",
day = "1",
doi = "10.1517/13543784.2015.985376",
language = "English (US)",
volume = "24",
pages = "329--344",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - The potential role of immunotherapy to treat colorectal cancer

AU - Amin, Manik

AU - Lockhart, Albert

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: Colorectal cancer (CRC) is the fourth most common cancer and the second leading cause of cancer-related death worldwide. Surgery, chemotherapy, radiation therapy and anti-angiogenic therapies form the backbone of treatment for CRC in various stages. Immunotherapy is frequently used either alone or in combination with chemotherapy for the treatment of various cancers such as melanoma, prostate cancer and renal cell cancer. Current CRC research is moving forward to discover ways to incorporate immunotherapies into the treatment of CRC.Areas covered: The aim of this review is to summarize the potential role of immunotherapy in CRC. Herein, the authors provide a brief overview of immune modulatory cells, immune surveillance and escape in CRC. They also review vaccine trials in addition to cytokines and monoclonal antibodies. This coverage includes ongoing trials and checkpoint inhibitors such as cytotoxic T lymphocyte antigen-1, programmed cell death-1, and PDL1.Expert opinion: Checkpoint inhibitors in combination with either chemotherapy or chemo-antiangiogenic-therapy may represent a future therapeutic approach for CRC incorporating immune system targeting. Given the success of immune-based therapy in other tumor types, the authors anticipate that a similar breakthrough in CRC will be forthcoming.

AB - Introduction: Colorectal cancer (CRC) is the fourth most common cancer and the second leading cause of cancer-related death worldwide. Surgery, chemotherapy, radiation therapy and anti-angiogenic therapies form the backbone of treatment for CRC in various stages. Immunotherapy is frequently used either alone or in combination with chemotherapy for the treatment of various cancers such as melanoma, prostate cancer and renal cell cancer. Current CRC research is moving forward to discover ways to incorporate immunotherapies into the treatment of CRC.Areas covered: The aim of this review is to summarize the potential role of immunotherapy in CRC. Herein, the authors provide a brief overview of immune modulatory cells, immune surveillance and escape in CRC. They also review vaccine trials in addition to cytokines and monoclonal antibodies. This coverage includes ongoing trials and checkpoint inhibitors such as cytotoxic T lymphocyte antigen-1, programmed cell death-1, and PDL1.Expert opinion: Checkpoint inhibitors in combination with either chemotherapy or chemo-antiangiogenic-therapy may represent a future therapeutic approach for CRC incorporating immune system targeting. Given the success of immune-based therapy in other tumor types, the authors anticipate that a similar breakthrough in CRC will be forthcoming.

KW - Colorectal cancer

KW - Immune modulatory cells

KW - Immune surveillance

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84923052907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923052907&partnerID=8YFLogxK

U2 - 10.1517/13543784.2015.985376

DO - 10.1517/13543784.2015.985376

M3 - Review article

C2 - 25519074

AN - SCOPUS:84923052907

VL - 24

SP - 329

EP - 344

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 3

ER -